DRUG
Tirzepatide
Treatment will occur over a 12-week period, with once-weekly injections of escalating doses every 3 weeks from 2.5mg to 10mg. Tirzepatide will be used in conjunction with Motivational Enhancement Therapy (MET).
Tirzepatide in the Treatment of Cannabis Use Disorder
Status
Not yet recruiting
Phase
Phase 3
Enrollment
15
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Cannabis is the most commonly used psychoactive substance in Canada. A sub-group of cannabis users develop Cannabis Use Disorder (CUD). CUD is a pattern of cannabis use that results in impairment in functioning, symptoms of tolerance, withdrawal, and distress. Several pharmacological and psychosocial interventions have been evaluated for their efficacy in treating CUD, however they lack high success rates. GLP-1RA's have shown promising results in reducing food and alcohol cravings and intake. Tirzepatide acts as both a GLP-1RA and a glucose-dependent insulinotropic polypeptide receptor agonist. Tirzepatide has been reported to reduce alcohol consumption, and therefore may have promising effects as a treatment for CUD. This study aims to evaluate the feasibility and tolerability of weekly injections of Tirzepatide combined with Motivational Enhancement Therapy in adults with CUD. This trial will be the first to examine the potential therapeutic effects of Tirzepatide in CUD.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jun 26, 2026
Study start
Aug 1, 2026
Primary completion
Jul 31, 2028
Study completion
Jul 31, 2028
Results posted
Not reported
Registry updated
Jul 1, 2026
Outcomes
What the study measures.
Primary outcomes
Tolerability of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder.
Time frame · From baseline to 12-week endpoint.
Tolerability will be measured by the percent of participants who discontinue the trial. Tolerability will also be measured by the percent of participants who reach the target dose.
Feasibility of Tirzepatide-Assisted-Psychotherapy for Cannabis Use Disorder.
Time frame · From baseline to 12-week endpoint.
Feasibility will be evaluated based on the number of people who contact the study team, percent of people that contact who are eligible and percent of eligible participants who enroll.
Secondary outcomes
Frequency and amount of cannabis use
Time frame · From baseline to 12-week endpoint.
The Enhanced Cannabis Timeline Follow Back (EC-TLFB) obtains information about frequency of cannabis use, amount used, types of cannabis products, and methods of administration.
Severity of Cannabis Use Disorder symptoms
Time frame · From baseline to 12-week endpoint
The Self-Reported Symptoms of Cannabis Use Disorder (SRSCUD) is a 13-item self-report form that allows individuals to rate the severity of their Cannabis Use Disorder on a scale from 1 to 4. Total scores range from 0 to 39, with a higher score indicating greater symptom severity.
Cannabis cravings
Time frame · From baseline to 12-week endpoint
The Marijuana Craving Questionnaire - Short Form (MCQ-SF) is a self-report 12-item questionnaire used to assess individual's cannabis craving experiences.
Cannabis withdrawal symptoms
Time frame · From baseline to 12-week endpoint
The Marijuana Withdrawal Checklist (MWC) is a self-report 15-item questionnaire used to assess symptoms of cannabis withdrawal. Participants rate items on a Likert scale from 0 (not at all) to 3 (severe) based on their most recent period of cannabis abstinence. Scores range from 0 to 45, with higher scores indicating greater withdrawal symptom severity.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Adults aged 18 and above * DSM-5 Cannabis Use Disorder diagnosis of at least moderate severity (4+ DSM-5 symptoms) * 4 or more days of cannabis use per week * Treatment seeking * A Body Mass Index (BMI) ≥ 22 Exclusion Criteria: * Meet DSM-5 criteria for Cluster A or B personality disorders and/or unstable current bipolar disorder, schizophrenia, or psychotic disorder * Comorbid severe DSM-5 Major Depressive Disorder * Present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study, as determined by the study physician and Columbia Suicide Severity Rating Scale * Any other mental health condition deemed incompatible by the study team * Meet DSM-5 criteria for alcohol or substance use disorder for any substance other than cannabis or tobacco in the past 6 months * Positive urine drug screen for any substance except cannabis * Concurrent addiction-focused psychotherapy in the past 6 months * Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months * A personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 * Current unstable medical condition * A lifetime diagnosis of Diabetes * Females who are pregnant/nursing, or individuals in reproductive age who do not consent to using birth control during the study * Concomitant treatment with: other GLP-1 agonists, Contrave, bupropion, naltrexone, acamprosate within the past year. No lifetime treatment with tirzepatide. * Significant literacy, visual, or hearing problems * Co-enrollment in a clinical drug trial
Study locations
1 registered sites.
Canada. Showing up to 24 locations stored in the fast local snapshot.
MacAnxiety Research Centre
Hamilton, Ontario, Canada
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Tirzepatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Obesity & Overweight
Not applicable
Recruiting
24
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.